Document Detail


Emerging drugs for perennial allergic rhinitis.
MedLine Citation:
PMID:  23186314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Allergic rhinitis (AR) is a high-prevalence disease, sustained by an IgE-triggered reaction with histamine release, followed by an inflammatory response which involves cells, mediators, cytokines and adhesion molecules. According to its duration, AR can be either intermittent or persistent. In the persistent form, the inflammatory component usually predominates.
AREAS COVERED: The current therapeutic strategy is based on antihistamines, antileukotrienes and on corticosteroids (which broadly act on inflammation). Allergen-specific immunotherapy is a biological response modifier that affects the immune response to allergens in a broad sense. The available pharmacotherapy is overall effective in controlling symptoms and inflammation, but safety concerns may be present (especially for prolonged treatments), and a proportion of patients remain uncontrolled. The available therapeutic innovations, as derived from the most recent literature are reviewed herein.
EXPERT OPINION: In the last years there have been very few innovative approaches to optimize the management of AR. These include new histamine receptor antagonists, combination therapy and strategies to selectively block relevant signaling pathways of the allergic reaction. Some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development.
Authors:
Giovanni Passalacqua; Giorgio Ciprandi
Related Documents :
24333964 - Immunotherapies and targeted therapies in medical oncology.
12761894 - Nitric oxide synthase i mediates osteoclast activity in vitro and in vivo.
14769514 - Role for osteoprotegerin in rheumatoid inflammation.
19049324 - Osteocyte apoptosis controls activation of intracortical resorption in response to bone...
21572994 - Antigen-independent ifn-γ production by human naïve cd4 t cells activated by il-12 pl...
19201824 - Involvement of tlr2 in innate response to bacillus anthracis infection.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  17     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-28     Completed Date:  2013-05-01     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  543-53     Citation Subset:  IM    
Affiliation:
Allergy & Respiratory Diseases, IRCCS S. Martino-IST-University of Genoa, Padiglione Maragliano, L.go R. Benzi 10, 16132 Genoa, Italy. passalacqua@unige.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allergens / immunology
Animals
Drug Design*
Histamine / metabolism
Histamine Antagonists / pharmacology,  therapeutic use*
Humans
Immunoglobulin E / immunology
Immunotherapy / methods
Rhinitis, Allergic, Perennial / drug therapy*,  immunology,  therapy
Signal Transduction / drug effects
Chemical
Reg. No./Substance:
0/Allergens; 0/Histamine Antagonists; 37341-29-0/Immunoglobulin E; 51-45-6/Histamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preop...
Next Document:  Emerging drugs for myelofibrosis.